Humana developed a novel health disparities measure to guide disparity-focused initiatives and track progress in achieving health equity.
The Covid-19 pandemic has exposed social and structural inequities leading to poor health outcomes, and policy makers and health care organizations are seeking ways to use data to inform strategies to improve equity. Although there is broad agreement that measurement is an essential tool, the best way to measure health inequities is an open question. Leaders at Humana have taken actions to better understand disparities in members’ health by developing a new health equity measure.
Building Accountability Into GLP-1 Benefit Design: Lessons From Delaware and Philadelphia
August 20th 2025Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and data-driven strategies in Philadelphia, Pennsylvania, and Wilmington, Delaware, for sustainable health programs.
Read More
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More